Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic Acid in Percutaneous Nephrolithotomy
NCT05947435Completed
- Sponsor
- Haseki Training and Research Hospital
- Start
- Jan 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of tranexamic acid in nephrolithiasis (3 arms), sponsored by Haseki Training and Research Hospital. Primary endpoints: Change in Hemoglobin and Hematocrit values at 48 hours and Postoperative need for blood transfusion at 48 hours. Started Jan 2022; status: completed.
02
Drugs
tranexamic acid
03
Conditions
nephrolithiasis
Beyond the preview
Go deeper on NCT05947435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05947435.